Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A van Hout

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Rheumatology (Oxford, England)|June 5, 2007
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United KingdomM F Botteman, J W Hay, M P Luo, et al.
Advances in Therapy|November 19, 2021
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making ApproachMarjanne A Piena, Sonja Kroep, Claire Simons, et al.
Current Medical Research and Opinion|May 1, 2010
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infectionsJ Floris S Logman, Jennifer Stephens, Bart Heeg, et al.
Health Economics|May 1, 1997
Modelling in economic evaluation: an unavoidable fact of lifeM J Buxton, M F Drummond, B A Van Hout, et al.
Pharmacoeconomics|January 19, 2006
Modelling the treated course of schizophrenia: development of a discrete event simulation modelBart Heeg, Erik Buskens, Martin Knapp, et al.
Infection Control and Hospital Epidemiology|December 1, 1996
Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgeryM F VandenBergh, J A Kluytmans, B A van Hout, et al.
Vox Sanguinis|February 21, 2009
Monitoring viral incidence rates: tools for the implementation of European Union regulationsM P Janssen, E A Cator, C L van der Poel, et al.
Vox Sanguinis|August 24, 2010
Survival after transfusion in the NetherlandsB A Borkent-Raven, M P Janssen, C L van der Poel, et al.
European Journal of Immunology|August 11, 2015
Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonistsMartin Kreutz, Ghaith Bakdash, Yusuf Dolen, et al.
Vox Sanguinis|March 6, 2010
The PROTON study: profiles of blood product transfusion recipients in the NetherlandsB A Borkent-Raven, M P Janssen, C L van der Poel, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Rheumatology (Oxford, England)|June 5, 2007
Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United KingdomM F Botteman, J W Hay, M P Luo, et al.
Advances in Therapy|November 19, 2021
An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making ApproachMarjanne A Piena, Sonja Kroep, Claire Simons, et al.
Current Medical Research and Opinion|May 1, 2010
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infectionsJ Floris S Logman, Jennifer Stephens, Bart Heeg, et al.
Health Economics|May 1, 1997
Modelling in economic evaluation: an unavoidable fact of lifeM J Buxton, M F Drummond, B A Van Hout, et al.
Pharmacoeconomics|January 19, 2006
Modelling the treated course of schizophrenia: development of a discrete event simulation modelBart Heeg, Erik Buskens, Martin Knapp, et al.
Infection Control and Hospital Epidemiology|December 1, 1996
Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgeryM F VandenBergh, J A Kluytmans, B A van Hout, et al.
Vox Sanguinis|February 21, 2009
Monitoring viral incidence rates: tools for the implementation of European Union regulationsM P Janssen, E A Cator, C L van der Poel, et al.
Vox Sanguinis|August 24, 2010
Survival after transfusion in the NetherlandsB A Borkent-Raven, M P Janssen, C L van der Poel, et al.
European Journal of Immunology|August 11, 2015
Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonistsMartin Kreutz, Ghaith Bakdash, Yusuf Dolen, et al.
Vox Sanguinis|March 6, 2010
The PROTON study: profiles of blood product transfusion recipients in the NetherlandsB A Borkent-Raven, M P Janssen, C L van der Poel, et al.
Pageof 13